■本范围综述旨在总结近期文献(2010-2022年)中关于手术使用SURGICEL进行术中止血所导致的并发症的报道。
■使用MEDLINE(OVID)进行了文献检索,Embase,和Cochrane中央对照试验注册中心(OVID)数据库。这些研究被分类为病例报告和其他研究类型,用于数据提取。数据提取采用Covidence,统计采用描述性。
■在筛选的560篇文章中,本文选择了73篇论文进行全文综述,其中70篇研究纳入了这篇综述。共有7,242名参与者被纳入研究(案例研究n=93,非其他人n=7149)。67/70纳入的研究报告了术中使用SURGICEL时的并发症。报告的并发症包括:SURGICEL诱发的肿块(肉芽肿,脓肿,血肿,囊肿)(n=25),出血性并发症(n=12),误诊为肿瘤的肿块,心血管,神经系统,和肝胆并发症,疼痛和感染。其他并发症包括:瘘管,勃起功能障碍,绒毛膜羊膜炎,肿胀,尿漏,肾功能衰竭,和过敏反应。
■报道术中使用SURGICEL相关并发症的出版物不断涌现。未来的研究应比较SURGICEL和替代止血剂之间的并发症类型和发生率。
UNASSIGNED: This review aims to summarize the findings from recent literature (2010-2022) reporting on complications that resulted from the surgical use of SURGICEL for intraoperative hemostasis.
UNASSIGNED: A literature search was conducted using the MEDLINE (OVID), Embase, and Cochrane Central Register of Controlled Trials - CENTRAL (OVID) databases. The studies were sorted into case reports and other study types for data extraction. Covidence was used for data extraction and statistics were descriptive.
UNASSIGNED: Of the total 560 articles screened, 73 papers were selected for a full-text review and 70 studies were included in this review. A total of 7,242 participants were included in the studies (case studies n = 93, others n = 7149). 67/70 of the included studies reported complications when SURGICEL was used intraoperatively. Reported complications included: SURGICEL induced masses (granulomas, abscesses, hematomas, cysts) (n = 25), hemorrhagic complications (n = 12), masses misdiagnosed as tumors, cardiovascular, nervous system, and hepatobiliary complications, pain, and infections. Other complications included: fistulas, erectile dysfunction, chorioamnionitis, swelling, urinary leak, renal failure, and anaphylaxis.
UNASSIGNED: Publications reporting on complications associated with the use of SURGICEL intraoperatively have continued to emerge. Future studies should compare how the types and rates of complications compare between SURGICEL and alternative hemostatic agents.